Accordingly, inhibition of the MAP kinase pathway (frequently activated in many solid tumors including BC) using a MEK inhibitor seems capable of increasing expression of MHC I and II, PD-L1 expression, tumor infiltration by CD8+ T cells, thereby sensitizing tumors to anti-PD-1 immunotherapy [69,70]. The gene discussed is CD8A; the disease is neoplasm.